Dr LiPuma received an undergraduate degree in biology from Canisius College in Buffalo, New York, in 1976 and an M.D. degree from St. Louis University School of Medicine in 1980. He completed residency training in pediatrics at the University of Michigan in 1983 and subspeciality fellowship training in pediatric infectious diseases at the University of Michigan in 1986. He held faculty positions in the Department of Pediatrics at the Medical College of Pennsylvania until 2000 when he returned to the University of Michigan. He currently is Professor of Pediatrics in the Medical School and Professor of Epidemiology in the School of Public Health. His laboratory is supported by grants from the Cystic Fibrosis Foundation and the National Institutes of Health. He serves on the CF Advisory Board of Novartis Pharmaceuticals. He is a member of the Pediatric Infectious Diseases Society and the Infectious Diseases Society of America. He has published in excess of 100 scientific papers related to infection in cystic fibrosis.
Research interests: Dr. LiPuma’s research focuses on bacterial infections in persons with cystic fibrosis (CF). His laboratory investigates the epidemiology, natural history, ecology, microbiology and virulence of opportunistic pathogens that cause respiratory tract infection in CF. The laboratory receives funding from the Cystic Fibrosis Foundation to serve as a national reference laboratory for the identification and genotyping of Burkholderia cepacia complex and related bacterial species. The laboratory also serves as a strain repository that currently includes some 20,000 characterized bacterial strains recovered from clinical and environmental sources. Funding from the National Institutes of Health supports several ongoing research projects. Current research projects include, (i) exploring the role of a Type IV Secretion System in the virulence of B. cenocepacia; (ii) investigating the therapeutic potential of lytic bacteriophage with activity against B. cepacia complex species; (iii) using comparative genomic analyses to discover genetic elements responsible for the enhanced virulence of ‘epidemic’ B. cenocepacia strains; (iv) developing high through put, sensitive, rapid diagnostics for CF related pathogens; and (v) determining differences in clinical outcomes associated with infection with species of the B. cepacia complex.
Address: University of Michigan School of Public Health
1150 W. Medical Center Dr,
8323 MSRB III, SPC 5646,
Ann Arbor, MI 48109
Tel: 734 615 5909,
Fax: 734 764 4279